ORPHA:79406
Late-onset junctional epidermolysis bullosa
Also known as: Epidermolysis bullosa progressiva · JEB-lo · Late-onset JEB
Publications
18
28.7th percentile
Trials
0
Interventional, condition-specific
Researchers
90
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A form of junctional epidermolysis bullosa characterized by onset in childhood or young adulthood of blistering that first occurs around nails, accompanied by nail and shedding, and then affects the hands and feet and, to a lesser extent, the elbows, and knees. Lesions heal with atrophic scarring. Other manifestations include disappearance of dermatoglyphs and palmoplantar hyperhidrosis. Extracutaneous involvement is restricted to soft tissue abnormalities of the oral cavity and enamel defects with development of caries.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019309
- UMLS:C4304724
Additional Mondo synonyms (1)
EB progressive
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
18 matched papers (11 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 10 for broader category junctional epidermolysis bullosa
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
18
18 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
18 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
11 in the last 10 years · high confidence · 28.7th percentile (publications denominator)
Phrase hits: 18 · MeSH hits: 0
Who's working on it?
90
Distinct author names in 18 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Jonkman MF3 papers · 2019Papers in Europe PMC
- 02Farokh Forghani S2 papers · 2025
Burn Research Center, Iran University of Medical Sciences, Tehran, Iran
Papers in Europe PMC - 03Irilouzadian R2 papers · 2025
Burn Research Center, Iran University of Medical Sciences, Tehran, Iran
Papers in Europe PMC - 04Pas HH2 papers · 2019Papers in Europe PMC
- 05Peñarrocha Diago M2 papers · 2020
Stomatology Department, Faculty of Medicine and Dentistry, University of Valencia, Spain.
Papers in Europe PMC - 06Saraee A2 papers · 2025
Department of Plastic and Reconstructive Surgery, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
Papers in Europe PMC - 07Shabbak A2 papers · 2025
Burn and Regenerative Medicine Research Center, Guilan University of Medical Sciences, Rasht, Iran
Papers in Europe PMC - 08Alessandrini A1 paper · 2024
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Papers in Europe PMC - 09Alsayer F1 paper · 2020
Royal National ENT and Eastman Dental Hospitals, University College London Hospitals, London, UK.
Papers in Europe PMC - 10Antal MA1 paper · 2020
University of Szeged, Faculty of Dentistry, Szeged, Hungary.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 10 trials are registered for junctional epidermolysis bullosa, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
10 interventional trials matched junctional epidermolysis bullosa, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: junctional epidermolysis bullosa
10
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06594393·RECRUITING·A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
Conditions: Epidermolysis Bullosa (EB) · Dystrophic Epidermolysis Bullosa · Junctional Epidermolysis Bullosa·Matched via name phrase
- NCT06917690·RECRUITING·A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Conditions: Epidermolysis Bullosa · Junctional Epidermolysis Bullosa · Epidermolysis Bullosa, Dystrophic · Epidermolysis Bullosa, Junctional·Matched via name phrase
- NCT03526159·RECRUITING·Gentamicin for Junctional Epidermolysis Bullosa
Conditions: Junctional Epidermolysis Bullosa·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Late-onset junctional epidermolysis bullosa" OR "Epidermolysis bullosa progressiva" OR "JEB-lo" OR "Late-onset JEB" OR "EB progressive"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Late-onset junctional epidermolysis bullosa" OR "Epidermolysis bullosa progressiva" OR "JEB-lo" OR "Late-onset JEB" OR "EB progressive"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"junctional epidermolysis bullosa"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:22:37.737Z
